Skip to main content

Table 1 Baseline characteristics of the study population by treatment group and gender

From: A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis

Characteristic Placebo (n = 79) ch-OSA (n = 87) Male (n = 46) Female (n = 120)
Age (years) 62.2 ± 7.7 61.7 ± 6.5 61.0 ± 7.2 62.3 ± 7.0
Women 55 (69.6) 65 (74.7) 0 120 (100)
Body mass index (kg/m2) 29.5 ± 5.2 29.5 ± 5.4 29.1 ± 4.7 29.6 ± 5.6
Menopausal Status 1 pre (1.5) 1 pre (1.8) - 2 pre (1.7)
0 peri (1.5) 1 peri 1 peri (0.8)
54 post (98.2) 63 post (96.9) 117 post (97.5)
Kellgren and Lawrence grade II 48 (60.8) 59 (67.8) 26 (56.5) 81 (67.5)
Kellgren and Lawrence grade III 31 (39.2) 28 (32.2) 20 (43.5) 39 (32.5)
Likert pain score 2 38 (48.1) 32 (36.8) 19 (41.3) 51 (42.5)
Likert pain score 3 41 (51.9) 55 (63.2) 27 (58.7) 69 (57.5)
WOMAC Total (/100 mm) 43.1 ± 20.3 40.9 ± 19.4 42.2 ± 21.5 41.9 ± 19.2
WOMAC Pain (/100 mm) 41.2 ± 20.3 38.2 ± 19.8 41.9 ± 20.9 38.7 ± 19.7
WOMAC Stiffness (/100 mm) 45.3 ± 24.6 44.0 ± 23.5 44.9 ± 23.4 44.5 ± 24.3
WOMAC Function (/100 mm) 43.4 ± 21.2 41.4 ± 19.8 42.0 ± 22.5 42.5 ± 19.7
Subject Global Assessment (/100 mm) 49.4 ± 21.8 50.1 ± 18.2 51.3 ± 22.4 49.2 ± 19.0
CTX-II/Creatinine (ng/mmol) 413.1 ± 189.6 430.4 ± 212.7 378.5 ± 162.8 441.0 ± 213.9
COMP (U/L) 10.8 ± 2.8 10.7 ± 2.8 11.0 ± 2.8 10.6 ± 2.8
Estradiol (ng/L) - - 35.5 ± 31.0 22.0 ± 36.2 a
  1. Data expressed as mean ± SD or n (%);-: not applicable; a significant difference between groups (men versus women); Number of patients without outliers for CTX-II: Placebo (n = 66), ch-OSA (n = 68); Number of patients without outliers for COMP: Placebo (n = 74), ch-OSA (n = 80)